A Smart + Strong Site
Subscribe to:
POZ magazine
IAS 2007 4th International AIDS Society Conference
on HIV Pathogenesis, Treatment and Prevention
Sydney, Australia
July 22-25, 2007

August 2, 2007
Prezista Superior to Kaletra for Treatment-Experienced Patients
Preliminary results from a major clinical trial have demonstrated that Prezista plus Norvir is more effective than Kaletra in treatment-experienced HIV-positive patients.
August 1, 2007
Lexiva vs. Reyataz: Comparable Efficacy
Lexiva or Reyataz, both combined with Norvir, are similar in their effectiveness. A second study suggests that the dose of Norvir currently used to boost Lexiva levels in the bloodstream can be halved without compromising effectiveness.
July 26, 2007
Norvir/Invirase Go Head-to-Head with Kaletra
Early results from a 48-week clinical trial comparing Norvir (ritonavir)-boosted Invirase (saquinavir) to Kaletra (lopinavir plus ritonavir) suggest that both options are working similarly well in patients starting therapy for the first time, although the rate of virologic failure has thus far been higher in the Norvir/Invirase group. 
Starting or Switching: Truvada Outpaces Combivir in Studies
Researchers have reported extended follow-up data from a clinical trial comparing two pairs of nucleoside reverse transcriptase inhibitors (NRTIs), both combined with Sustiva (efavirenz): once-daily Truvada (tenofovir plus lamivudine) plus Emtriva (emtricitabine) versus Combivir (zidovudine plus lamivudine). 

August 2, 2007
NNRTI Etravirine Effective for Treatment-Experienced Patients
Studies reviewed at the fourth IAS Conference in Sydney indicate that Tibotec's NNRTI etravirine, combined with the company's PI Prezista, is safe and effective for treatment-experienced HIV-positive patients.
August 1, 2007
PRO 140 Shows Promise in Single-Dose Study
Researchers have reported encouraging results from an early study of PRO 140, an experimental HIV entry inhibitor.
July 25, 2007
Sustiva Edges Out Celsentri in Treatment Newbies
A clinical trial has found that Pfizer's CCR5-blocking entry inhibitor, Celsentri (maraviroc), when used by patients starting HIV treatment for the first time, appears somewhat inferior to standard-of-care Sustiva (efavirenz).
July 24, 2007
Merck’s Isentress Comparable to Sustiva as a First-Time Treatment
Results from an ongoing clinical trial of Isentress (raltegravir) suggest that it has comparable efficacy to Sustiva (efavirenz) after 48 weeks of treatment.
Vicriviroc Shows Benefits, Continues Development
The AIDS Clinical Trials Group has reported additional data from a clinical trial of vicriviroc, Schering-Plough’s experimental entry inhibitor currently in the Phase II stage of development.
Rilpivirine (TMC-278) Has Metabolic Edge Over Sustiva
Additional side-effect data from a clinical trial of rilpivirine (TMC-278) indicates that it causes minimal changes in lipid (fat) and glucose (sugar) levels over 48 weeks of treatment.

July 26, 2007
Is HIV Treatment Actually Reducing Heart Attack Risk?
New study data reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention indicates that HIV treatment—despite its often negative effects on blood lipid levels—may actually reverse artery hardening that can lead to a heart attack or stroke. 
July 25, 2007
Simple Test Can Help Prevent Abacavir Allergy
A clinical trial has confirmed that a simple lab test for a human gene can help prevent a serious allergic reaction caused by abacavir, the active ingredient in Ziagen and a component of Epzicom (Kivexa) and Trizivir. 
High Risk of Kidney Problems in HIV
There is a high rate of kidney problems in HIV-positive patients, according to a French study reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, in Sydney.
July 24, 2007
HIV Infection Linked to Higher Skin Cancer Risk
Skin cancer rates are higher among HIV-positive people than among the general population, according to data reported at IAS 2007 in Sydney.
July 23, 2007
Crystal Meth Linked to Lower CD4s in Positive People
HIV-positive people using crystal methamphetamine have lower CD4 cell counts than their HIV-positive counterparts who don’t use the drug, according to new data reported at the IAC Conference in Sydney.

July 23, 2007
Timed Intercourse Plus PrEP for Low-Risk Natural Conception
HIV-negative women who use pre-exposure prophylaxis (PrEP) immediately prior to engaging in carefully timed sexual intercourse with their antiretroviral-treated HIV-positive male partners may further reduce their already low risk of being exposed to the virus.

July 22, 2007
AIDS Down Under: IAS Conference Begins in Sydney
The IAS Conference on HIV Pathogenesis, Treatment and Prevention began with calls for even greater vigilance to ensure universal access to HIV prevention and treatment, along with an expansion of research to inform and strengthen the global response to HIV.

July 26, 2007
Beyond Condoms: Medical Approaches For Prevention
Regan Hofmann talks with Dr. Nancy Padian about PrEP, microbicides, and circumcision, and asks "when can my boyfriend and I stop using condoms."
July 25, 2007
Pipeline Preview: All The New AIDS Drugs Coming Soon
Peter Staley reviews all the new experimental AIDS drugs with Dr. Joe Eron, including two non-nukes, and two new classes of drugs: CCR5 and integrase inhibitors.
Simple Test Eliminates Abacavir Risk
Peter Staley asks Professor Simon Mallal from the Royal Perth Hospital about a simple new genetic test that accurately predicts if a patient is at risk for an allergic reaction to abacavir (Ziagen).
July 24, 2007
A Positive Papua New Guinean Speaks Out Against Stigma
Regan Hofmann interviews Maura Elaripe Mea, the first HIV-positive woman to come forward publicly in her country. Through Igat Hope, the national network of people living with HIV/AIDS in PNG, Maura and others fight AIDS discrimination while spreading information and hope.
The Latest on Lipo: Advances & Setbacks
Dr. Don Kotler discusses the latest from Sydney, both good and bad, on lipodystrophy treatments and cardiovascular risk in people with HIV.
Which HIV Meds Cause Lipoatrophy?
In this videocast, Dr. Eric Daar provides an overview of which nukes, non-nukes, and protease inhibitors might cause fat loss, and which ones probably won't.
Are We Starting Treatment Early Enough?
In this videocast, Dr. Fred Gordin explains why many experts think we might be waiting too long to put patients on HIV treatment.
July 23, 2007
An Eccentric Professor Expounds on Growing Old With HIV
A videocast interview with Professor Brian Gazzard, an expert on HIV and aging.
July 22, 2007
Fauci Defends Bush's AIDS Legacy
Peter Staley interviews Tony Fauci about his research on HIV "eradication," President Bush's AIDS legacy, why he likes gay men and Republicans, and that letter he wrote supporting Scooter Libby.

Our IAS conference coverage is generously sponsored by Abbott Laboratories, Gilead Sciences and GlaxoSmithKline.
Abbott Gilead GlaxoSmithKline

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.